Targeted cancer drug trial offers hope for frail patients
NCT ID NCT07126561
Summary
This study is testing a targeted cancer drug called trastuzumab deruxtecan (Enhertu) in people newly diagnosed with advanced HER2-positive stomach or esophageal cancer who are too frail for standard combination chemotherapy. The main goal is to see how well the drug shrinks tumors and to monitor side effects. Participants will receive the drug by IV infusion and be closely monitored for safety and response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 POSITIVE NEWLY DIAGNOSED METASTATIC ESOPHAGEAL, GASTRIC, GEJ CANCER PATIENTS WITH AN ECOG PERFORMANCE STATUS OF 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.